Format

Send to

Choose Destination
Kidney Int. 2012 Feb;81(4):351-62. doi: 10.1038/ki.2011.380. Epub 2011 Dec 14.

Treatment of chronic kidney disease.

Author information

1
Nephrology Division, Department of Medicine, Albert Einstein College of Medicine, Bronx, New York, USA.

Abstract

Treatment of chronic kidney disease (CKD) can slow its progression to end-stage renal disease (ESRD). However, the therapies remain limited. Blood pressure control using angiotensin-converting enzyme (ACE) inhibitors or angiotensin II receptor blockers (ARBs) has the greatest weight of evidence. Glycemic control in diabetes seems likely to retard progression. Several metabolic disturbances of CKD may prove to be useful therapeutic targets but have been insufficiently tested. These include acidosis, hyperphosphatemia, and vitamin D deficiency. Drugs aimed at other potentially damaging systems and processes, including endothelin, fibrosis, oxidation, and advanced glycation end products, are at various stages of development. In addition to the paucity of proven effective therapies, the incomplete application of existing treatments, the education of patients about their disease, and the transition to ESRD care remain major practical barriers to better outcomes.

PMID:
22166846
DOI:
10.1038/ki.2011.380
[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center